Hybrigenics’ main focus is the development of inecalcitol as a niche treatment for leukaemia. In February it presented encouraging initial results for inecalcitol in combination with oral imatinib in chronic myeloid leukaemia (CML), with 43% of patients responding in a Phase II study that will complete in H218. A Phase II trial in acute myeloid leukaemia (AML) is ongoing with data expected in H119. Inecalcitol is Phase III-ready for chronic lymphocytic leukaemia (CLL) where it slowed pr
12 May 2017
Inecalcitol shows promise in CML, R&D refocus
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Inecalcitol shows promise in CML, R&D refocus
Hybrigenics SA Class A (ALHYG:PAR) | 0 0 0.0% | Mkt Cap: 25.2m
- Published:
12 May 2017 -
Author:
Juan Pedro Serrate -
Pages:
11
Hybrigenics’ main focus is the development of inecalcitol as a niche treatment for leukaemia. In February it presented encouraging initial results for inecalcitol in combination with oral imatinib in chronic myeloid leukaemia (CML), with 43% of patients responding in a Phase II study that will complete in H218. A Phase II trial in acute myeloid leukaemia (AML) is ongoing with data expected in H119. Inecalcitol is Phase III-ready for chronic lymphocytic leukaemia (CLL) where it slowed pr